Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
181
resultados
Última actualización
13/01/2026 [07:15:00]
Resumen de: WO2026006246A1
The disclosure provides an evaluation of the virome in health and disease of the oral-gut-brain axis, in particular, periodontitis, irritable bowel disease (IBD) and Alzheimer's Disease (AD). For Alzheimer's disease, a striking feature was found via metagenomics of brain autopsy specimens - the presence of parvoviridae (comprised of erythoviruses and erythroparvoviruses) in the brains of individuals diagnosed with Alzheimer's Disease (AD) but not in brains from age-matched healthy individuals without a medical diagnosis of AD. For IBD, For Periodontitis and IBD, an analysis revealed the top 20 most abundant viral and bacterial species in saliva samples from individuals with periodontal disease or with a healthy periodontium and the top viral and bacterial species in stool samples from individuals with irritable bowel syndrome or with gastrointestinal health. Building upon these discoveries, a number of diagnostic methods and materials for AD and IBD are described herein.
Resumen de: TW202535470A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/ or diagnostic use in a subgroup of patients having ulcerative colitis.
Resumen de: WO2024176230A1
The present disclosure relates to reversible phase variations in bacteria e.g., residing in a microbiome or any environment, and uses thereof in determining a physiological and/or environmental condition or state of a subject or a media and/or or habitat. The present disclosure thus provides methods and personalized therapeutic methods and kits.
Resumen de: US2025389717A1
The present disclosure provides methods for assessing mucosal healing in a patient with Crohn's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.
Resumen de: WO2024240709A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: WO2025257752A1
This invention relates to methods of detecting inflammatory disease in a subject by detecting circulating microclots, based on combined detection or co-detection of fibrin amyloid microclots and components from Neutrophil Extracellular Traps in a sample from the subject, wherein an increased presence of fibrin amyloid microclots and NETs in the sample compared to a control or reference value is indicative of inflammatory disease in the subject. The invention also relates to kits for detecting circulating microclots to be used in the methods of detecting inflammatory disease.
Resumen de: WO2025259880A1
Provided herein are materials and methods for determining responsiveness of any therapy that enhances regulatory T cell (Treg) function in the treatment of inflammatory bowel disease (IBD). The materials and methods provided herein may be used to determine low dose IL- 2 responsiveness in a subject having an inflammatory bowel disease. The materials and methods can be used to determine low dose IL- 2 responsiveness in a blood sample prior to administering a low dose IL-2 therapy.
Resumen de: EP4663746A2
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.
Resumen de: AU2024260758A1
Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.
Resumen de: US2025376514A1
The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL-17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
Resumen de: WO2025253423A1
A new microbial consortium for use in a rapid screening method for irritable bowel syndrome (IBS) and possibly as a target for the therapeutic treatment of an IBS condition in a subject.
Resumen de: WO2025253316A1
The present disclosure relates to the use of angiotensin-converting enzyme and/or angiotensin-converting enzyme 2 as a fecal biomarker for the diagnosis of a disease or disorder related to the renin-angiotensin-aldosterone system, and also to the use of angiotensin-converting enzyme and angiotensin-converting enzyme 2 isoforms as fecal biomarkers for the detection of dysbiosis.
Resumen de: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: AU2024273758A1
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Resumen de: WO2025250163A1
Apparatus and associated methods relate to evaluating impurity content in battery materials. In an illustrative example, a battery material impurity assessment system (BMIAS) may include a slurry mixing system and an impurity extraction system (IBS). The slurry mixing system, for example, may include a motor configured to rotate a vertical axis of a slurry container. For example, the motor may pause a movement of the slurry container when the vertical axis is rotated at a predetermined angle. For example, the IBS may include a translatable magnetic mass (TMM) enclosed within a sheath. For example, by operating a position of the TMM, the IBS may release non-target impurity and retain target substances. In some implementations, the target substance may be ionized by an acid treatment solution rapidly without direct heating. In some implementations, the target substances may be dispersed on a conductive filter to be directly used in subsequent analysis. Various embodiments may advantageously rapid high precision and rapid impurity testing for battery manufacturing.
Resumen de: US2025366831A1
A system and a method for diagnosis and monitoring of inflammatory bowel diseases (IBD) in a subject are provided. The system includes a memory and a control system. The memory stores machine-readable instructions. The control system includes one or more processors configured to execute the machine-readable instructions. Ultrasound image data associated with the gastrointestinal tract of the subject is received. The received ultrasound image data is processed to output a set of ultrasound image features. The output set of ultrasound image features is received, as an input to an automated algorithm. A set of radiomic features is extracted from the input set of ultrasound image features, using the automated algorithm. The ultrasound image data is classified as normal or abnormal based on the extracted set of radiomic features, the classifying being an output of the automated algorithm.
Resumen de: WO2025244478A1
The present invention relates to a novel microorganism and a use thereof for preventing, alleviating, or treating intestinal diseases. The strain according to one embodiment has effects of inhibiting intestinal atrophy and reducing bloody stools, and thus is useful for the prevention, amelioration, or treatment of intestinal diseases. In addition, since the strain is significantly reduced in the patient group, the strain can be used for early diagnosis of intestinal diseases or selection of a risk group.
Resumen de: WO2024156739A1
The invention relates to a method for identifying a multi-parameter phenotype of microbiota. The method comprises (i) providing a sample comprising microbiota, (ii) labeling said microbiota with multiple labels, each of which binds a phenotypic parameter of said microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. The invention further relates to a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Resumen de: MX2025010187A
Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.
Resumen de: NZ762152A
The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.
Resumen de: WO2025244988A1
Disclosed are methods of characterizing, diagnosing, monitoring, and/or treating an individual with Crohn's Disease (CD) comprising detecting, in a biological sample obtained from the individual, a plurality of biomarkers. The biomarkers may be used for one or more of predicting remission of CD in an individual, determining longitudinal assessment of response to a biologic therapy, predicting or determining response status of the individual to an anti-tumor necrosis factor (TNF) therapy. Further disclosed are systems and compositions for use with the disclosed methods.
Resumen de: WO2025244478A1
The present invention relates to a novel microorganism and a use thereof for preventing, alleviating, or treating intestinal diseases. The strain according to one embodiment has effects of inhibiting intestinal atrophy and reducing bloody stools, and thus is useful for the prevention, amelioration, or treatment of intestinal diseases. In addition, since the strain is significantly reduced in the patient group, the strain can be used for early diagnosis of intestinal diseases or selection of a risk group.
Nº publicación: WO2025245006A1 27/11/2025
Solicitante:
THE CLEVELAND CLINIC FOUND [US]
THE CLEVELAND CLINIC FOUNDATION
Resumen de: WO2025245006A1
Provided herein arc systems and methods for testing exhaled breath from a subject (e.g., suspected of having inflammatory bowel disease, IBD) to determine the level of at least one volatile organic compound (e.g., 1 or 5 or 8 compounds). In certain embodiments, one receives test results, such as an elevated or decreased level of a particular volatile organic compound, and this is used to determine if a subject has IBD or needs treatment with an IBD treating agent. In other embodiments, the subject is treated with an IBD treating agent, and optionally tested again to monitor treatment (e.g., tested over days, weeks, or months). In other embodiments, the subject is determined to have moderate or severe IBD, or mild or no IBD.
BOPI
Sede Electrónica
